FDA Approves Takeda's Orzeyful, a First-in-Class Treatment for Narcolepsy

The U.S. Food and Drug Administration (FDA) on Wednesday approved Orzeyful, an oral medication from Takeda Pharmaceuticals for the treatment of narcolepsy. According to the health regulator, the drug is the first approved therapy to target all symptoms of the rare sleep disorder by addressing its underlying cause.

A Novel Mechanism of Action

Orzeyful is a twice-daily pill that works by directly targeting the loss of orexin signaling in the brain. Narcolepsy type 1 is caused by the loss of brain cells that produce orexin, a key chemical messenger regulating wakefulness and muscle tone. The FDA noted that prior to this approval, no medicine for narcolepsy type 1 acted on the orexin system as a unified treatment.

The approval was based on data from two clinical studies, which showed that patients treated with Orzeyful had significant improvements in their ability to stay awake during the day compared to those who received a placebo.

Market and Patient Context

Narcolepsy type 1 is a rare, chronic neurological condition that causes excessive daytime sleepiness, sudden loss of muscle tone (cataplexy), cognitive symptoms, and disrupted nighttime sleep. Takeda estimates the condition affects approximately 120,000 people in the United States.

Ad

As the first treatment to address the core orexin deficiency, Orzeyful represents a significant development for this patient population, potentially offering a more comprehensive approach than existing symptom-management therapies.

Next Steps for Availability

Takeda stated that the drug's commercial launch is pending a review by the U.S. Drug Enforcement Administration (DEA). The DEA will determine the controlled substance classification for Orzeyful, a ruling the company expects within 90 days.

Following the DEA's classification, Takeda plans to make the drug available to U.S. healthcare providers and patients through a specialty pharmacy network.